Medications called GLP-1 receptor agonists (GLP-1-RAs) have become widely used in recent years. These drugs are prescribed for people with type 2 diabetes and for weight loss. As more people begin using them, doctors want to better understand how safe they are in real-world settings—not just in controlled clinical trials.
This study looked at over 300,000 patients across the United States to compare GLP-1 drugs such as Semaglutide (Ozempic, Wegovy), Liraglutide (Victoza, Saxenda), and Dulaglutide (Trulicity) with other common treatments. The goal was simple: find out how often serious health problems happen and whether these drugs are safer, riskier, or about the same as other options when people taken them in the real world.
How the Study Was Done
Researchers used a large U.S. healthcare database with medical and prescription records from hundreds of thousands of patients.
They focused on two groups:
- People with type 2 diabetes
- People using medications for weight loss without diabetes
For each group, they compared people starting GLP-1 drugs to people starting other treatments used for the same purpose. This helped make the comparison more realistic, since doctors often choose between these options in real life.
After starting the medication, patients were followed for about 6 months to 1 year. During that time, researchers tracked serious health events, including:
- Heart attack or stroke
- Gallbladder problems
- Liver injury
- Mental health events
- Death
To make the results fair and accurate, the researchers adjusted for many differences between patients, like age, health conditions, and medical history. This helps ensure that any differences seen are more likely due to the medications—not other factors.
What They Found About Side Effects
One of the clearest findings in this study involved the gallbladder. People taking GLP-1 drugs were more likely to be hospitalized for gallbladder or bile duct problems compared to those using other medications. This pattern appeared in both people with type 2 diabetes and those using the drugs for weight loss. While the overall risk was still relatively low, it was consistent across groups and seemed to increase with longer use.
The researchers also saw slightly higher rates of some digestive issues, such as bowel-related problems, but these findings were less certain and occurred less often. Importantly, most of the serious side effects studied were uncommon, even in such a large group of patients.
Overall, the results suggest that while GLP-1 medications are generally safe, they may carry a small but meaningful increased risk for certain conditions—especially those affecting the gallbladder.
What About Heart Health?
Are you hoping these drugs may have heart benefits? In this study, the results may surprise you.
The researchers found that rates of heart attacks and strokes were about the same between GLP-1 drugs and other treatments.
This does not mean the drugs don’t help the heart—but in this real-world study:
- They did not clearly outperform other medications
- Especially in people without high heart risk
One reason may be that the comparison drugs also protect the heart, making differences harder to see.
There are Benefits
In people with diabetes, GLP-1 drugs were linked to a lower risk of acute liver injury compared to another common drug group.
This is interesting because these GLP-1 medications are already being studied for liver-related conditions.
The study also found:
- No clear increase in suicidal thoughts
- No strong evidence of increased thyroid cancer risk (though results were less certain in weight-loss users)
What This Means for Everyday People
For most people, serious side effects were rare overall. That’s important. Even when risks were higher, they still did not happen often.
Here’s the big picture:
- GLP-1 drugs appear generally safe, but not risk-free
- They may increase the chance of gallbladder problems
- They do not clearly reduce heart risks more than other drugs in everyday use
- They may offer some liver-related benefits
Another key takeaway: many people stopped taking these medications within months, which may affect how well they work long-term.
Why This Study Matters
Most drug safety data comes from clinical trials, where conditions are tightly controlled. This study is different—it shows what happens in the real world, where patients vary widely and don’t always take medications perfectly.
That makes the findings especially useful for:
- Doctors choosing between treatments
- Patients deciding if the benefits are worth the risks
As these medications continue to grow in popularity, studies like this help paint a clearer, more realistic picture of what to expect.
Bottom Line
GLP-1 medications remain powerful tools for treating diabetes and supporting weight loss. But like any medication, they come with trade-offs.
Understanding both the benefits and risks helps people make smarter, more informed decisions about their health.
Source
Hurwitz SR, Lanes S, Quimbo T, Papazian A, White J, Fisher V, et al. Comparative safety of glucagon-like peptide 1 receptor agonists (GLP-1-RAs) in type 2 diabetes and chronic weight management: a real-world data study. Pharmacoepidemiol Drug Saf. 2025;34(9):e70214. Available from: https://doi.org/10.1002/pds.70214
